3 Big Drugmakers Most Likely to Buy Incyte


The company's oncology portfolio makes it an attractive target.But a target for whom? stand out as three of the most likely suitors for Incyte. Here's why these big drugmakers could be interested in making a significant acquisition.



from Biotech News